TNFSF13B and chronic graft versus host disease: Early clinical trials of BAFF blocking with belimumab demonstrated beneficial effects on both acute and chronic GVHD, and these results suggest that elevated BAFF levels contribute to B-cell activation in patients with active chronic GVHD (17, 21).